| Code | CSB-RA897523MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to belimumab, targeting TNFSF13B (tumor necrosis factor superfamily member 13B), also known as B-lymphocyte stimulator (BLyS) or BAFF (B-cell activating factor). TNFSF13B is a cytokine that plays a critical role in B-cell survival, maturation, and differentiation by binding to receptors on B lymphocytes. Elevated levels of TNFSF13B have been implicated in autoimmune diseases, particularly systemic lupus erythematosus (SLE) and other B-cell mediated disorders, where excessive B-cell activity contributes to autoantibody production and immune dysregulation.
Belimumab was the first biologic therapy approved for SLE and functions by neutralizing soluble TNFSF13B, thereby reducing B-cell survival signals and modulating aberrant immune responses. This biosimilar antibody provides researchers with a valuable tool for investigating TNFSF13B biology, B-cell dependent immune mechanisms, and autoimmune disease pathogenesis. It is suitable for exploring therapeutic mechanisms, validating TNFSF13B as a target in various disease models, and advancing understanding of B-cell homeostasis in immunological research.
There are currently no reviews for this product.